Pharmacogenomics Journal

Papers
(The median citation count of Pharmacogenomics Journal is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
CYP3A5 and POR gene polymorphisms as predictors of infection and graft rejection in post-liver transplant patients treated with tacrolimus - a cohort study52
Drug genetic associations with COVID-19 manifestations: a data mining and network biology approach40
Influence of UGT1A1 and SLC22A6 polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study24
Impact of genetic variation in CYP2C19, CYP2D6, and CYP3A4 on oxycodone and its metabolites in a large database of clinical urine drug tests22
Pharmacogenomics of Clozapine-induced agranulocytosis: a systematic review and meta-analysis21
Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: a randomized trial21
Development of an extensive workflow for comprehensive clinical pharmacogenomic profiling: lessons from a pilot study on 100 whole exome sequencing data19
Genetic factors contributing to late adverse musculoskeletal effects in childhood acute lymphoblastic leukemia survivors19
Genetic variants associated with cardiometabolic abnormalities during treatment with selective serotonin reuptake inhibitors: a genome-wide association study18
Clinical utility of pharmacogenetics in a psychiatric and primary care population15
The expression level of Neuronal Calcium Sensor 1 can predict the prognosis of cytogenetically normal AML15
Correction to: One year of experience with combined pharmacokinetic/pharmacogenetic monitoring of anti-TNF alpha agents: a retrospective study15
Knowledge and attitudes of medical and pharmacy students about pharmacogenomics: a systematic review and meta-analysis14
Inosine monophosphate dehydrogenase type 2 polymorphism IMPDH2 3757T>C (rs11706052) and 12-month evolution of the graft function in renal transplant recipients on mycophenolate-based immunosuppress13
Clinical and economic outcomes of a pharmacogenomics-enriched comprehensive medication management program in a self-insured employee population12
Real-world economic evaluation of prospective rapid whole-genome sequencing compared to a matched retrospective cohort of critically ill pediatric patients in the United States12
AHR-dependent genes and response to MTX therapy in rheumatoid arthritis patients11
Genetic association analysis and frequency of NUDT15*3 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease in a large Dutch cohort11
Appraisal and development of evidence-based clinical decision support to enable perioperative pharmacogenomic application11
Network pharmacology prediction, molecular docking and in vitro experiment explored the potential mechanism of Gaoyuan’an capsule in improving hypoxia tolerance10
Association between functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to rituximab in patients with autoimmune diseases: a meta-analysis10
Cost-utility analysis of pharmacogenomics-guided tacrolimus treatment of Slovenian patients undergoing kidney transplantation in the U-PGx PREPARE study10
HLA-DQA1*05 and upstream variants of PPARGC1B are associated with infliximab persistence in Japanese Crohn’s disease patients10
Correction to: A pharmacogenomic study on the pharmacokinetics of tacrolimus in healthy subjects using the DMETTM Plus platform10
Opioid use disorder risk alleles in self-reported assigned African American/Afro-Caribbean and European biogeographical genetic ancestry groups and in males and females9
Unveiling the association between HMG-CoA reductase inhibitors and bladder cancer: a comprehensive analysis using Mendelian randomization, animal models, and transcriptomics8
STRIPE partners in precision medicine series: pharmacist perspective7
Evaluation of the EMPAR study population on the basis of metabolic phenotypes of selected pharmacogenes7
Targeted next-generation sequencing of genes involved in Warfarin Pharmacodynamics and pharmacokinetics pathways using the Saudi Warfarin Pharmacogenetic study (SWAP)7
Correction to: PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors7
Contribution of plasma levels of VEGF-A and angiopoietin-2 in addition to a genetic variant in KCNAB1 to predict the risk of bevacizumab-induced hypertension7
Pharmacogenomic study—A pilot study of the effect of pharmacogenomic phenotypes on the adequate dosing of verapamil for migraine prevention6
Genetic markers of early response to lurasidone in acute schizophrenia6
Cytochrome P450-2D6 activity in people with codeine use disorder6
Assessment of clinically actionable pharmacogenetic markers to stratify anti-seizure medications6
Cost-utility analysis of pharmacogenomics-guided tacrolimus treatment in Austrian kidney transplant recipients participating in the U-PGx PREPARE study6
Plasma concentrations of venetoclax and Pharmacogenetics correlated with drug efficacy in treatment naive leukemia patients: a retrospective study6
Correction to: Pharmacogenetic interventions to improve outcomes in patients with multimorbidity or prescribed polypharmacy: a systematic review6
The INGENIOUS trial: Impact of pharmacogenetic testing on adverse events in a pragmatic clinical trial5
Association study of candidate DNA-repair gene variants and acute graft versus host disease in pediatric patients receiving allogeneic hematopoietic stem-cell transplantation5
Integrating epidemiology and genomics data to estimate the prevalence of acquired cysteine drug targets in the U.S. cancer patient population5
Pharmacoepigenomics circuits induced by a novel retinoid-polyamine conjugate in human immortalized keratinocytes5
Non-steroidal anti-inflammatory drug target gene associations with major depressive disorders: a Mendelian randomisation study integrating GWAS, eQTL and mQTL Data4
A machine learning model using SNPs obtained from a genome-wide association study predicts the onset of vincristine-induced peripheral neuropathy4
Meta-analysis of pharmacogenetic clinical decision support systems for the treatment of major depressive disorder4
Polygenic risk scores analyses of psychiatric and metabolic traits with antipsychotic-induced weight gain in schizophrenia: an exploratory study4
Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance)4
Pharmacogenomic biomarker information on drug labels of the Spanish Agency of Medicines and Sanitary products: evaluation and comparison with other regulatory agencies4
Implementation of CYP2D6 copy-number imputation panel and frequency of key pharmacogenetic variants in Finnish individuals with a psychotic disorder3
Implementation of pharmacogenetic testing in pediatric oncology: barriers and facilitators assessment at eight Canadian academic health centres3
STRIPE partners in precision medicine series: provider perspective3
Using ChatGPT to predict the future of personalized medicine3
A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care3
Pharmacokinetic and neuroimmune pharmacogenetic impacts on slow-release morphine cancer pain control and adverse effects3
PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors3
KDR genetic predictor of toxicities induced by sorafenib and regorafenib3
ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairment3
Impact of CYP2C19 metaboliser status on SSRI response: a retrospective study of 9500 participants of the Australian Genetics of Depression Study3
Understanding general practitioner and pharmacist preferences for pharmacogenetic testing in primary care: a discrete choice experiment3
The association between the number of HLA risk alleles and drug allergy and its implications for HLA screening – a case-control study3
A NOS1AP gene variant is associated with a paradoxical increase of the QT-interval shortening effect of digoxin3
Economic evaluation in psychiatric pharmacogenomics: a systematic review3
Systematic identification of cancer pathways and potential drugs for intervention through multi-omics analysis2
A systematic review on the cost effectiveness of pharmacogenomics in developing countries: implementation challenges2
Pharmacogenetic interventions to improve outcomes in patients with multimorbidity or prescribed polypharmacy: a systematic review2
A Decade of Pharmacogenetic Studies in Jordan: A Systemic Review2
A blockchain-based framework to support pharmacogenetic data sharing2
Effect of CYP2C19 polymorphisms on antidepressant prescription patterns and treatment emergent mania in bipolar disorder2
Nine-gene pharmacogenomics profile service: The Mayo Clinic experience2
A single nucleotide polymorphism-based formula to predict the risk of propofol TCI concentration being over 4 µg mL−1 at the time of loss of consciousness2
Polymorphisms at CYP enzymes, NR1I2 and NR1I3 in association with virologic response to antiretroviral therapy in Brazilian HIV-positive individuals2
Investigating genetic variants for treatment response to selective serotonin reuptake inhibitors in syndromal factors and side effects among patients with depression in Taiwanese Han population2
0.11517596244812